References
- Garg A, Garg J, Rao YK, Upadhyay GC, Sakhuja S. Prevalence of dengue among clinically suspected febrile episodes at a teaching hospital in North India. J Infect Dis Immun 2011; 3:85-9
- Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL Green S, Vaughn DW, Ennis FA, Endy TP. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007; 369:1452-9; PMID:17467515; http://dx.doi.org/10.1016/S0140-6736(07)60671-0
- Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100-3; PMID:11827812; http://dx.doi.org/10.1016/S0966-842X(01)02288-0
- Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, Kongsin S, Jiamton S, Garrido F, Montoya R, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009; 80:846-55; PMID:19407136
- World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: WHO; 2009; accessed on 2013 Oct 06 Available from: http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf
- Directorate of National Vector Borne Disease Control Programme. Report. Nirman Bhawan, New Delhi: Ministry of Health & Family Welfare, Government of India; 2013
- Edelman R. Dengue vaccines: approach to the finish line. Clin Infect Dis 2007; 45:S56-60; PMID:17582571; http://dx.doi.org/10.1086/518148
- Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am J Trop Med Hyg 2002; 66:264-72; PMID:12139219
- Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five to twelve year old Thai children. Pediatr Infect Dis J 2004; 23:99-109; PMID:14872173; http://dx.doi.org/10.1097/01.inf.0000109289.55856.27
- Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R Chambonneau L, Deauvieau F, Lang J, Guy B. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in vero cells (VDV3). Vaccine 2006; 24:4914-26; PMID:16632108; http://dx.doi.org/10.1016/j.vaccine.2006.03.066
- Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:24-31; PMID:14740952
- Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 2013; 88:73-88; PMID:23208878; http://dx.doi.org/10.4269/ajtmh.2012.12-0361
- Wan SW, Lin CF, Wang S, Chen YH, Yeh TM, Liu HS Anderson R, Lin YS. Current progress in dengue vaccines: a review. J Biomed Sci 2013;20:37-46; PMID:23758699; http://dx.doi.org/10.1186/1423-0127-20-37
- World Health Organization. Questions and answers on dengue vaccines: phase IIb study of CYD-TDV. Geneva: WHO; 2012
- Clements DE, Coller BG, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28:2705-15; PMID:20097152; http://dx.doi.org/10.1016/j.vaccine.2010.01.022